Neuromod Devices Appoints New General Counsel

Summary: Neuromod Devices has appointed Tom Maher as its general counsel. His extensive legal and business experience in the life sciences industry will help support the company’s global expansion into the Lenire tinnitus treatment market.

Conclusions:

Tom Maher joins Neuromod Devices with over 25 years of experience in the life sciences sector, including corporate and operational advisory roles, and will strengthen the company’s leadership position as it executes on its strategic initiatives.
As general counsel, Maher will oversee Neuromod’s legal, governance and compliance affairs, a critical role as the company scales and navigates complex international markets.
Maher’s appointment comes as Neuromod continues to expand Lenire’s global reach, following recent expansion into the U.S. and Europe, underscoring the company’s commitment to redefining tinnitus treatment worldwide.

Neuromod Device, the medical technology company behind the Lenire tinnitus treatment, announced the appointment of Tom Maher as general counsel, effective July 5, 2024.

Maher most recently served as Chief Operating Officer, Legal Advisor and Company Secretary of Amarin Pharmaceuticals Ireland and has a successful track record in three public company management positions.

“I am pleased to announce the appointment of Tom as General Counsel of Neuromod Devices. Tom’s extensive experience in international business and corporate operations in the life sciences industry will be an invaluable asset to Neuromod Devices as we continue to redefine tinnitus care on a global scale,” said Ross O’Neil, PhD, founder and CEO of Neuromod Devices.

Life Sciences Industry Veteran

Maher joins Neuromod Devices Ltd. with more than 25 years of corporate law and business experience in the international life sciences industry, including biopharmaceuticals, biotechnology and medical technology.

In his role as General Counsel, Maher will be responsible for Neuromod’s legal and contractual affairs, corporate transactions, governance and corporate compliance.

“I am excited to join the Neuromod leadership team as the company advances the commercialization of Lenire,” says Maher. “I look forward to working with Ross and the broader team to lead the execution of Neuromod’s ambitious strategic plans in 2024 and beyond.”

Maher’s appointment comes as Neuromod continues to expand Lenire’s global availability. Earlier this year, the organization increased the number of hearing and tinnitus care practices it works with in the United States to more than 80. Neuromod also expanded Lenire’s availability in Europe, forming partnerships with additional practices in Spain, Italy, and the Principality of Monaco.

Photo: Neuromod